Category: Forbes

Medicare Pays More Money To Doctors Taking Care Of Rich Patients. Here’s Why.

Here’s a much more pernicious bias in Medicare’s reimbursement policies.

‘RIP Our Hero’: Li Wenliang’s Death Sparks Rare Outrage From Chinese Citizens Towards Government

Chinese social media users⁠—referred to as “netizens”⁠—took to Weibo and WeChat to vent mounting anger and grief.

Coronavirus Hits Electronics Manufacturing Hard, Companies Are Scrambling

This is “new product development” season, when electronics companies start working to build products they plan to ship for Christmas later this year. Coronavirus has thrown a wrench in those plans.

Coronavirus Outbreak On Quarantined Japan Cruise Ship Spreads. 61 Passengers Now Affected

Sixty-one people are now affected by coronavirus on a quarantined cruise ship in Japan. What does this mean for the other passengers stuck onboard?

First Peanut Allergy Drug Gets FDA Thumbs Up

Palforzia is now approved for use in individuals aged 4 through 17 who have a confirmed diagnosis of peanut allergy.

My Doctor Sent Me To A Jerk

If forced to choose between an abrasive but skillful surgeon and a personable but less skilled surgeon, the abrasive surgeon is the way to go.

New Cell-Based Immunotherapy Shows Positive Results In Initial Trial On Blood Cancers

A new type of cell-based immunotherapy has extended the lives of several people with blood cancer who had no treatment options left.

Wuhan Doctor Who Tried To Warn China About Coronavirus Dies Of The Disease At Age 34

Li Wenliang’s social media posts about the disease led to a reprimand from Wuhan police.

Trump’s SOTU Message On Health Care: More Rhetoric Than Substance

President Trump’s bombast and hyperbole were on full display at this week’s State of the Union address. With respect to health care this week’s speech was conspicuously long on rhetoric and short on facts.

Feel The Bern: Presidential Race Throws Cold Water On Health Insurance Mega-Mergers

The U.S. health insurance market, roiled by transformative deals in recent years, will likely face a lull in major deal activity in 2020 while firms await critical federal election outcomes.